{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:34:34Z","timestamp":1787016874530,"version":"build-2736575974"},"reference-count":38,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100012781","name":"Merck & Co. | MSD K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2022,4,27]]},"abstract":"<jats:p>\n                    Carbapenem-resistant Enterobacterales and carbapenem-resistant\n                    <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n                    strains pose a global threat. Antibacterial activity of imipenem\/relebactam (IMR) against clinical isolates of these bacteria from several global regions has been shown; however, as yet there are no reports on Japanese isolates.\n                  <\/jats:p>","DOI":"10.1128\/spectrum.02235-21","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T09:01:54Z","timestamp":1649840514000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["<i>In Vitro<\/i>\n                    Antibacterial Activity of Imipenem\/Relebactam against Clinical Isolates in Japan"],"prefix":"10.1128","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0319-3958","authenticated-orcid":true,"given":"Dai","family":"Kurihara","sequence":"first","affiliation":[{"name":"Japan Development, MSD K.K., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Microbiological Testing Group, Infectious Diseases Testing Department, Clinical Laboratory Center, Medical Solution Segment, LSI Medience Corporation, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Kishi","sequence":"additional","affiliation":[{"name":"Microbiological Testing Group, Infectious Diseases Testing Department, Clinical Laboratory Center, Medical Solution Segment, LSI Medience Corporation, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1943-4648","authenticated-orcid":true,"given":"Yoshikazu","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Mori","sequence":"additional","affiliation":[{"name":"Japan Development, MSD K.K., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl354"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198733030-00001"},{"key":"e_1_3_2_4_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2021","unstructured":"Clinical and Laboratory Standards Institute. 2021. Performance standards for antimicrobial susceptibility testing, 31st ed. CLSI supplement M100. CLSI, Wayne, PA, USA.","edition":"31"},{"key":"e_1_3_2_5_2","unstructured":"World Health Organization. 2017. Prioritization of pathogens to guide discovery research and development of new antibiotics for drug-resistant bacterial infections including tuberculosis. WHO Geneva Switzerland."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-019-1522-7"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01860.x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2011.00065"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt178"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz530"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02209-16"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky107"},{"key":"e_1_3_2_13_2","first-page":"567","article-title":"In vitro antimicrobial activity of ceftolozane\/tazobactam against clinical isolates from Japan","volume":"66","author":"Hidaka Y","year":"2018","unstructured":"Hidaka Y, Kishi N, Matsumoto S, Yoshinari T, Mori M. 2018. In vitro antimicrobial activity of ceftolozane\/tazobactam against clinical isolates from Japan. Jpn J Chemother 66:567\u2013577.","journal-title":"Jpn J Chemother"},{"key":"e_1_3_2_14_2","unstructured":"Hilbert DW DeRyke CA Moise P Motyl MR Hackel MA Young K. 2021. Relebactam increases susceptibility of Enterobacterales and Pseudomonas aeruginosa to imipenem in both imipenem-susceptible and imipenem-nonsusceptible gram-negative bacteria\u2013Global SMART 2017\u20132019. Poster 01590 31st Eur Congr Clin Microbiol Infect Dis (ECCMID) Virtual Meeting 9 to 12 July 2021."},{"key":"e_1_3_2_15_2","unstructured":"Young K Hilbert DW DeRyke CA Sahm DF Motyl MR. 2021. Relebactam enhances the activity of imipenem against Burkholderia cepacia complex (BCC) isolates SMART 2016\u20132019. World Microbe Forum Virtual Meeting 20 to 24 June 2021."},{"key":"e_1_3_2_16_2","unstructured":"Hilbert DW DeRyke CA Losada MC Chen LF Moise PA Young K. 2021. Relebactam increases imipenem activity against imipenem-nonsusceptible and -susceptible Pseudomonas aeruginosa and Enterobacterales : assessment of isolates from RESTORE-IMI 2. Poster 1071331 IDWeek 2021 Virtual Meeting 29 September to 3 October 2021."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13158"},{"key":"e_1_3_2_18_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2021. Breakpoint tables for interpretation of MICs and zone diameters version 11.0 2021. EUCAST V\u00e4xj\u00f6 Sweden."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa121"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0851-9"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa206"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/36.2.335"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.045799-0"},{"key":"e_1_3_2_24_2","first-page":"1","article-title":"Surveillance of in vitro susceptibilities to levofloxacin and various antibacterial agents for 11,762 clinical isolates obtained from 69 centers in 2013","volume":"69","author":"Yamaguchi K","year":"2016","unstructured":"Yamaguchi K, Tateda K, Ohno A, Ishii Y, Murakami H. 2016. Surveillance of in vitro susceptibilities to levofloxacin and various antibacterial agents for 11,762 clinical isolates obtained from 69 centers in 2013. Jpn J Antibiot 69:1\u201325.","journal-title":"Jpn J Antibiot"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0924-8579(02)00099-7"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02190-17"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2015.1070097"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.997206"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161207779313731"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1039\/C5MD00344J"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa201"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa284"},{"key":"e_1_3_2_33_2","volume-title":"Manual of clinical microbiology","author":"Carroll KC","year":"2019","unstructured":"Carroll KC, Pfaller MA, Landry ML, McAdam AJ, Patel R, Richter SS, Warnock DW. 2019. Manual of clinical microbiology, 12th ed. ASM Press, Washington, DC, USA.","edition":"12"},{"key":"e_1_3_2_34_2","unstructured":"Ministry of Health Labour and Welfare Ministry of Education Culture Sports Science and Technology. 2002. Ethical guidelines for epidemiologic research. Ministry of Health Labour and Welfare and Ministry of Education Culture Sports Science and Technology Tokyo Japan. https:\/\/www.mhlw.go.jp\/general\/seido\/kousei\/i-kenkyu\/ekigaku\/0504sisin.html."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02091-17"},{"key":"e_1_3_2_36_2","volume-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 8th ed. CLSI document M11-A8. CLSI, Wayne, PA, USA.","edition":"8"},{"key":"e_1_3_2_37_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 11th ed. CLSI standard M07. CLSI, Wayne, PA, USA.","edition":"11"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00036-08"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.12.5945-5949.2005"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.02235-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.02235-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T09:40:42Z","timestamp":1651052442000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.02235-21"}},"subtitle":[],"editor":[{"given":"Ahmed","family":"Babiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4,27]]}},"alternative-id":["10.1128\/spectrum.02235-21"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.02235-21","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"2021-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02235-21"}}